Analysts Set Oxford Biomedica plc (LON:OXB) Price Target at GBX 687

Oxford Biomedica plc (LON:OXB) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is GBX 687.

OXB has been the subject of a number of research analyst reports. Stifel Nicolaus restated a “buy” rating and issued a GBX 950 target price on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Jefferies Financial Group initiated coverage on Oxford Biomedica in a research note on Monday, March 23rd. They issued a “buy” rating and a GBX 827 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research note on Friday, January 9th.

Oxford Biomedica Stock Performance

Shares of OXB stock opened at GBX 550 on Friday. The firm has a market capitalization of £664.95 million, a price-to-earnings ratio of -20.43 and a beta of 1.04. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67. The business has a fifty day moving average of GBX 689.87 and a 200 day moving average of GBX 663.85. Oxford Biomedica has a 1 year low of GBX 232.50 and a 1 year high of GBX 952.

Oxford Biomedica (LON:OXB) last issued its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, research analysts expect that Oxford Biomedica will post -31.0799998 earnings per share for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.